In summary, CTLA4 promoter methylation seems to play a role within the epigenetic regulation of CTLA-4 expression in HNSCC and its microenvironment and significantly correlates with therapy response and progression-free survival under anti-PD-1 therapy. Here, CTLA4 is linked to head and neck squamous cell carcinoma.